Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

Authors: Rona M. Smith¹,²*, Rachel B. Jones², Ulrich Specks³, Simon Bond⁴, Marianna Nodale⁴, Reem Aljayyousi⁵, Jacqueline Andrews⁶, Annette Bruchfeld⁷, Brian Camilleri⁸, Simon Carette⁹, Chee Kay Cheung⁵, Vimal Derebail¹⁰, Tim Doulton¹¹, Lindsy Forbess¹², Shouichi Fujimoto¹³, Shunsuke Furuta¹⁴, Ora Gewurz-Singer¹⁵, Lorraine Harper¹⁶, Toshiko Ito-Ihara¹⁷, Nader Khalidi¹⁸, Rainer Klocke¹⁹, Curry Koening²⁰, Yoshinori Komagata²¹, Carol Langford²², Peter Lanyon²³, Raashid Luqmani²⁴, Hiroyumi Makino²⁵, Carol A. McAlear²⁶, Paul Monach²⁷, Larry Moreland²⁸, Kim Mynard², Patrick Nachman²⁹, Christian Pagnoux³⁰, Fiona Pearce³¹, Chen Au Peh³², Charles Pusey³³, Dwarakanathan Ranganathan³⁴, Rennie Rhee³⁵, Robert Spiera³⁶, Antoine Srieh³⁷, Vladimir Tesar³⁸, Giles Walters³⁹, Michael Weisman¹², Caroline Wroe³⁷, Peter A. Merkel³⁶ and David R.W. Jayne¹,²$. 

*corresponding author

$ joint senior authors

Email: Ronasmith@doctors.net.uk; Postal address: Box 118, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ, United Kingdom

¹ University of Cambridge, United Kingdom

² University of Cambridge Hospitals NHS Foundation Trust, United Kingdom

³ Mayo Clinic College of Medicine, Rochester, Minnesota, United States of America

⁴ Cambridge Clinical Trials Unit, University of Cambridge Hospitals NHS Foundation Trust, United Kingdom

⁵ Leicester General Hospitals, Leicester, United Kingdom

⁶ Chapel Allerton Hospital, Leeds, United Kingdom

⁷ Karolinska University Hospital, Sweden

⁸ Ipswich Hospital, United Kingdom

⁹ Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

¹⁰ University of North Carolina, Chapel Hill, North Carolina, United States of America

¹¹ Kent and Canterbury Hospital, United Kingdom

¹² Cedars-Sinai Medical Center, Los Angeles, California, United States of America

¹³ Miyazaki University, Miyazaki city, Japan
14 Chiba University, Japan
15 University of Michigan, Ann Arbor, Michigan, United States of America
16 Queen Elizabeth Hospital, Birmingham, United Kingdom
17 Kyoto University, Japan
18 St Joseph's Healthcare, McMaster University, Hamilton, Ontario, Canada
19 Russells Hall Hospital, Dudley, United Kingdom
20 University of Utah, Salt Lake City, Utah, United States of America
21 Kyorin University, Tokyo, Japan
22 Cleveland Clinic, Cleveland, Ohio, United States of America
23 Nottingham University Hospitals, United Kingdom
24 Oxford University Hospitals, United Kingdom
25 Okayama University, Japan
26 Division of Rheumatology and Department of Epidemiology, Biostatistics, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
27 Brigham and Women’s Hospital, Boston, Massachusetts, United States of America
28 University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
29 University of Minnesota, Minneapolis, Minnesota, United States of America
30 Royal Adelaide Hospital, Australia
31 Imperial College, London, United Kingdom
32 Royal Brisbane and Women's Hospital, Australia
33 Hospital for Special Surgery, New York, New York, United States of America
34 Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
35 Charles University, Prague, Czech Republic
36 Canberra Hospital, Australia
37 James Cook University Hospital, Middlesbrough, United Kingdom
ClinicalTrials.gov identifier: NCT01697267

Keywords: ANCA-associated vasculitis, RITAZAREM, rituximab, azathioprine, randomized clinical trial.

Competing Interests: Dr Smith reports grants from Roche during the conduct of the study. Dr Jones reports grants from GlaxoSmithKline, personal fees from ChemoCentryx outside the submitted work. Dr Specks reports grants from Genentech, during the conduct of the study; grants from ChemoCentryx, grants from BMS, grants from GSK, personal fees from Astra Zeneca, outside the submitted work. Dr Bruchfeld reports grants and personal fees from Astra Zeneca, personal fees from ChemoCentryx, personal fees from Merck/MSD, personal fees from Abbvie outside the submitted work. Dr Cheung reports grants from GlaxoSmithKline, grants and consultancy fees from Retrophin outside the submitted work. Dr Langford reports grants from Genentech during the conduct of the study. Dr Khalidi reports personal fees and non-financial support from Roche, non-financial support from Bristol Meyers Squibb outside the submitted work. Dr Koening reports other from Genentech, other from Roche outside the submitted work. Dr Luqmani reports grants from Arthritis Research UK, grants from GlaxoSmithKline, grants from MRC, grants from University of Oxford Innovation Fund, grants from Canadian Institutes of Health Research, grants from The Vasculitis Foundation, grants from Celgene, grants from Vifor, personal fees from Grunenthal, personal fees from GSK, personal fees from InflaRx, personal fees from Medpace, personal fees from MedImmune, personal fees from Roche, outside the submitted work. Dr Makino reports personal fees from AbbVie, personal fees from Boehringer-Ingelheim, personal fees from Teijin, outside the submitted work. Dr Monach reports personal fees from Kiniksa, personal fees from ChemoCentryx, personal fees from Celgene, personal fees from Insmed, outside the submitted work. Dr Nachman reports other from Chemocentryx, other from InflaRx, other from Omeros, other from Aurinia outside the submitted work. Dr Pagnoux reports grants and personal fees from Roche, personal fees from ChemoCentryx, grants and personal fees from GlaxoSmithKline, personal fees from Sanofi, personal fees from InflaRx outside the submitted work. Dr Pearce reports grants from Vifor pharma outside the submitted work. Dr Spiera reports grants from GlaxoSmithKline, grants from chemocenturyx, grants from Roche/Genentech, grants from BIPI, personal fees from GlaxoSmithKline, personal fees from chemocenturyx. Dr Sreih reports personal fees from Bristol-Myers Squibb, other from Alexion outside the submitted work. Dr Tesar reports other from Abbvie, other from Amgen, other from Boehringer-Ingelheim, other from Calliditas, other from Chemocenturyx, other from FMC, other from Retrophin outside the submitted work. Dr Merkel reports personal fees from AbbVie, grants and personal fees from Biogen, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Boeringher-Ingeheim, grants and personal fees from Celgene, grants and personal fees from ChemoCentryx, CSL Behring, grants and personal fees from Genentech/Roche, grants and personal fees from Genzyme/Sanofi, grants and personal fees from GlaxoSmithKline, grants and personal fees from InflaRx, personal fees from Insmed, personal fees from Jannsen, personal fees from Kiniksa, grants from Kypha, personal fees from Sparrow, grants from TerumoBCT outside the submitted work. Dr. Jayne
reports grants from Roche/Genentech, during the conduct of the study; grants from Sanofi-Genzyme, grants and personal fees from Chemocentryx, grants and personal fees from GSK, grants from Roche/Genentech, personal fees from Takeda, personal fees from Insmed, personal fees from Astra-Zeneca, personal fees from Infla-RX, personal fees from Chugai, personal fees from Boehringer-Ingelheim outside the submitted work. Dr. Al-Jayyousi, Dr Andrews, Dr Bond, Dr. Camilleri, Dr Carette, Dr Derebail, Dr Doulton, Dr Forbes, Dr Fujimoto, Dr Furuta, Dr Gewurz-Singer, Dr Ito-hara, Dr Klocke, Dr Komogata, Dr Lanyon, C McAlear, Dr Moreland, K Mynard, Dr Nodale, Dr Peh, Dr Pusey, Dr. Ranganathan, Dr Rhee, Dr Walters, Dr Weisman, Dr Wroe have nothing to disclose.

Contributorship: Dr Smith, Prof Jayne and Prof Merkel conceived and designed the study. Dr Specks, Dr Jones and Dr Bond were also involved in study design. Dr Smith, Dr Bond, Dr Nodale, Prof Jayne and Prof Merkel analysed the data and interpreted the results. Dr Smith wrote the manuscript with support from Prof Jayne and Prof Merkel. All authors collected data and contributed critical appraisal to the final manuscript.

Funding: RITAZAREM is funded by grants from Versus Arthritis (formerly Arthritis Research UK) (Grant number 18706) and Roche/Genentech (MA28150). The Vasculitis Clinical Research Consortium (VCRC) (U54 AR057319 and U01 AR5187404) is part of the United States National Institutes of Health Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Science (NCATS). The VCRC is funded through collaboration between NCATS, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and has received funding from the National Center for Research Resources (U54 RR019497). The Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan. This research was also supported by the National Institute for Health Research (NIHR), Cambridge Biomedical Research Centre, and the Cambridge Clinical Trials Unit (CCTU).

Acknowledgements: The RITAZAREM trial is directed by the European Vasculitis Society (EUVAS) and the Vasculitis Clinical Research Consortium (VCRC). The primary sponsor is Cambridge University Hospitals NHS Foundation Trust and there are collaboration and data-sharing agreements with the University of Pennsylvania and the University of Miyazaki and Okayama University in Japan. Additional RITAZAREM co-investigators were: Dr Y Arimura (Kyorin University, Japan); Dr M Clarkson (Cork University Hospital, Ireland); Dr J de Zoysa (North Shore Hospital, Auckland, New Zealand); Dr T Endo (Kitano Hospital, Japan); Dr Y Hamano (Tokyo Metropolitan Geriatric Hospital, Japan); Dr H Kono (Teikyo University Hospital, Tokyo, Japan); Dr S Lawman (Brighton Royal Sussex County Hospital, UK); Dr E Muso (Kitano Hospital, Japan); Dr K Sada (Okayama University, Japan); Dr R Smith (Ipswich Hospital, UK); Dr K Suzuki (Teikyo University, Japan); Dr T Tsukamoto (Kitano Hospital, Japan); Dr S Uchida (Teikyo University Hospital, Tokyo, Japan); Dr A Vaglio (University of Parma, Italy); Dr R Watts (Ipswich Hospital, UK).
**Ethical Approval:** An initial favourable ethical opinion was granted by NRES Committee East of England – Cambridge South: REC reference: 12/EE/0230 on 24 July 2012. US approvals: Cedars-Sinai Medical Center Institutional Review Board: Pro00031367; Cleveland Clinic Institutional Review Board: 13-666; Hospital for Special Surgery Institutional Review Board: 13114; Mount Sinai Hospital Research Ethics Board: 12-0231-A; St. Joseph's Hospital Hamilton Integrated Research Ethics Board: 13-037; University of Pittsburgh Institutional Review Board: PRO13020329; University of Pennsylvania Office of Regulatory Affairs: 816166; The Mayo Clinic, University of Michigan, University of North Carolina, and the University of Utah all deferred to the University of Pennsylvania Ethics board and fall under the University of Pennsylvania approval number. Japanese ethics committee numbers: University of Miyazaki 2013-126; Chiba University 97; Kitano Hospital P14-01-002; Okayama University m05002; Kyorin University H26-031; Teikyo University 14-031; TMGH 260201.

**Data Sharing:** De-identified participant data can be requested from the corresponding author.

**Patient and public involvement:** Patients were involved in the design, conduct and dissemination of this research via national patient groups including the Vasculitis Foundation and Vasculitis UK.

**Key Messages:**

What is already known about this subject?
Rituximab is increasingly being used as a remission induction agent in ANCA associated vasculitis.

What does this study add?
This large prospective cohort provides further efficacy and safety data for the use of rituximab in patients specifically with relapsing disease.

How might this impact on clinical practice?
Rituximab in conjunction with glucocorticoids is now an established induction strategy in ANCA associated vasculitis.
ABSTRACT

Objectives:
Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into the induction phase of the RITAZAREM trial.

Methods:
Patients relapsing with granulomatosis with polyangiitis or microscopic polyangiitis were prospectively enrolled and received remission-induction therapy with rituximab (4 x 375 mg/m²) and a higher- or lower-dose glucocorticoid regimen, depending on physician choice: reducing from either 1 mg/kg/day or 0.5 mg/kg/day to 10 mg/day by 4 months. Patients in this cohort achieving remission were subsequently randomized to receive one of two regimens to prevent relapse.

Results:
188 patients were studied: 95/188 (51%) male, median age 59 years (range 19-89), prior disease duration 5.0 years (range 0.4-34.5). 149/188 (79%) had previously received cyclophosphamide and 67/188 (36%) rituximab. 119/188 (63%) of relapses had at least one major disease activity item, and 54/188 (29%) received the higher-dose glucocorticoid regimen.

171/188 (90%) patients achieved remission by 4 months. Only six patients (3.2% of the study population) did not achieve disease control at month 4. Four patients died in the induction phase due to pneumonia (2), cerebrovascular accident (1), and active vasculitis (1). 41 severe adverse events occurred in 27 patients, including 13 severe infections.

Conclusions:
This large prospective cohort of patients with relapsing ANCA-associated vasculitis treated with rituximab in conjunction with glucocorticoids, demonstrated a high level of efficacy for the re-induction of remission in patients with AAV who have relapsed, with a similar safety profile to previous studies.
INTRODUCTION

Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the major subgroups of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). These conditions are characterized by leucocyte infiltration of blood vessel walls, fibrinoid necrosis, and vascular damage, and are usually associated with the presence of circulating ANCA(1).

Prior to the availability of effective treatment, AAV had a mortality of 93% within two years, primarily due to renal and respiratory failure(2). The introduction of glucocorticoids and cyclophosphamide, which became established treatment for this disease in the 1980s, markedly improved survival, inducing remission at one year in approximately 80% of patients. However, relapsing disease is common with over 50% of patients experiencing a relapse within five years, and the majority suffering treatment-related toxicity(3-5).

B-lymphocytes have been implicated in the pathogenesis of AAV. Rituximab is a murine/human chimeric monoclonal antibody directed against the CD20 antigen found on the surface of B-lymphocytes, and results in B cell depletion. Rituximab was shown to be non-inferior to cyclophosphamide for induction of remission in AAV, and superior to cyclophosphamide for the treatment of relapsing disease (6, 7). Rituximab became a licensed therapy for remission induction of AAV in 2011.

Fixed-interval, repeat-dosing of rituximab was shown to be superior to azathioprine as a maintenance strategy following induction of remission cyclophosphamide in a trial of 117 patients with predominantly newly-diagnosed AAV (8). The optimal strategy to maintain remission following induction of remission with rituximab, especially for treatment of relapse, is not clear. RITAZAREM was an international, randomized, controlled trial designed to assess whether rituximab is superior to azathioprine for the maintenance of remission following induction of remission with rituximab and glucocorticoids in patients with relapsing AAV. In this trial, fixed-interval, repeat doses of rituximab were compared to daily azathioprine for maintenance of remission.

Since all patients received rituximab for induction of remission in the RITAZAREM trial, this is the largest reported prospective cohort of patients with relapsing AAV to receive treatment with rituximab for induction of remission. This first report outlines the efficacy and safety of rituximab with either higher or lower dose glucocorticoids for induction of remission in a large prospective cohort of patients with relapsing AAV.
METHODS:

The details of the RITAZAREM protocol have been previously published(9). In summary, RITAZAREM trial has three phases:

1) An induction phase (Months 0 to 4): eligible patients enrolled at time of disease relapse received rituximab (4 weekly doses of 375 mg/m²) and glucocorticoids;

2) A maintenance phase (months 4 to 24): four months after enrolment, participants who achieved remission (defined as a Birmingham Vasculitis Activity Score for Wegener’s granulomatosis (BVAS/WG) ≤ 1 and prednisone/prednisolone dose ≤ 10 mg/day) were randomized in 1:1 ratio to receive 1000 mg rituximab at four-monthly fixed intervals or daily azathioprine (2 mg/kg/day).

3) A follow-up phase: clinical follow-up after completion of therapy with either rituximab or azathioprine (minimum of 12, maximum of 24 months).

This paper reports on the first, induction phase of the trial, prior to randomisation.

Participants:

Participants were aged over 15 years and had a diagnosis of GPA or MPA according to Chapel Hill Consensus Conference definitions (10), and a current or historical positive test for PR3- or MPO-ANCA. All patients had disease relapse defined by one major or three minor disease activity items on the BVAS/WG and had previously achieved remission following at least 3 months of induction therapy, with a combination of glucocorticoids and an immunosuppressive agent (cyclophosphamide, rituximab, methotrexate, or mycophenolate mofetil).

Key exclusion criteria included the receipt of any biological B-cell-depleting agents within the previous 6 months, alemtuzumab or anti-thymocyte globulin (ATG) within the previous 12 months, or intravenously administered immunoglobulin (IVIg), plasma exchange, or anti-TNF treatment within the previous 3 months. Patients with other multisystem autoimmune diseases, such as eosinophilic granulomatous with polyangiitis (eGPA), systemic lupus erythematosus (SLE), anti-glomerular basement membrane (GBM) disease or cryoglobulinaemic vasculitis, or history of malignancy within the past 5 years were also excluded.

Participants were recruited from 29 centers in 7 countries.

Interventions, Induction Therapy:

Rituximab: Rituximab 375 mg/m²/week was administered in four doses.

Glucocorticoids: Investigators chose from one of two glucocorticoid regimens taking into consideration disease severity and local prescribing practices. Schedule 1A had a glucocorticoid starting dose of 1 mg/kg/day (maximum 60 mg daily) and 1B a starting dose
of 0.5 mg/kg/day (maximum 30mg daily), both tapering to 10 mg daily by month 4. Deviation from the protocol-specified tapering glucocorticoid regimen was defined as a 25% higher or lower glucocorticoid dose, averaged over 2 weeks. Patients could also receive a maximum cumulative dose of 3000 mg IV methylprednisolone, between 14 days prior to enrolment and 7 days after enrolment.

**Other treatments:** Prophylaxis to prevent *pneumocystis (carinii) jiroveci* infection and/or to prevent osteoporosis were recommended according to local practice. Plasma exchange could be administered during the induction period following local practice. However, rituximab was not administered within 48 hours before a plasma exchange treatment.

**Assessments:** Evaluations (including clinical, biochemical, and patient-reported outcomes) were performed at 0, 1.5, 3, and 4 months.

**Power calculation:** Enrolment was set to be open until at least 160 patients were randomized at their month 4 visits. It was anticipated that 190 patients would be required in order to randomize 160 patients. Details of how the sample size was determined have been previously published(9)

**Definitions:** Remission was defined as a BVAS/WG of 1 or less with a prednisone/prednisolone dose of 10mg/day or less by four months.

**Statistical methods:** Continuous variables are expressed as medians and interquartile ranges. Categorical variables are presented as percentages and frequencies. A set of univariate logistic regression analyses to predict remission at month 4 for candidate factors was performed. Estimates of marginal odds ratios, with 95% confidence intervals and p-values are presented. The statistical comparisons were not formally powered or pre-specified in the protocol so these results must be interpreted with caution. Data were analysed using R version 3.6.1.
RESULTS:

Baseline demographics:

188 patients were enrolled into the trial. Patient disposition throughout the 4-month induction period is shown in the consort diagram (Figure 1) and baseline demographics in Table 1. 95/188 (51%) patients were male, with a median age of 59 years (range 19-89) and prior disease duration of 5.0 years (range 0.4-34.5). 149/188 (79%) patients had previously received cyclophosphamide (median dose 9 grams (range 0.15-301) and 67/188 (36%) had received rituximab (median dose 3910 mg (range 1000-16000)). At enrolment, 60/188 (32%) patients were on an oral immunosuppressive agent: (35/188 (19%) azathioprine; 12/188 (6%) mycophenolate mofetil; and 13/188 (7%) methotrexate), each of which were stopped as per protocol. 137/188 (73%) had a history of a positive test for PR3-ANCA, and 51/188 (37%) for MPO-ANCA. 119/188 (63%) of relapses had at least one major disease activity item, and 54/188 (29%) patients received the higher-dose glucocorticoid regimen. The median BVAS/WG at enrolment was 5, (range 3-14). Distribution of baseline disease manifestations included: ear, nose, and throat: 120/187 (64.2%) patients, renal: 88 (47.1%), and respiratory involvement: 69 (36.9%).

The median number of body systems previously affected by vasculitis was 5 (range 0-10). Prior organ involvement included renal in 127/188 (67.6%) patients, lung in 115/188 (61.2%) patients, and ear nose and throat in 138/188 (73.4%) patients. Hypertension was common, affecting 93/199 (49.5%) patients. 23/188 (12.2%) patients had diabetes mellitus at enrolment; 29/188 (15.4%) chronic lung disease and 20/188 (10.6%) had previously suffered from malignancy.

Treatment exposure:

The median total dose of rituximab in the induction phase was 2937 mg (range 1552-4320 mg) and cumulative oral glucocorticoid exposure in the 4-month induction phase was 3010 mg (2485-7875 mg) in the 1A higher dose induction regimen and 1960 mg (1715-3535 mg) in the 1B lower dose induction regimen. There was no difference in cumulative glucocorticoid exposure between patients that achieved and did not achieve remission (median dose 1960mg in both groups (1A range: 1715-3010; 1B range 1715-7875). 25% of patients deviated from the specified glucocorticoid tapering regimen at some point in the induction phase.

Disease response:

171/188 (90%) patients achieved remission at month 4 (Figure 2). Of the 17 patients who did not achieve remission by month 4, 13 (76%) had PR3-ANCA positive disease, and 10 (59%) had ear, nose, and throat involvement at baseline. 14/17 (82%) patients who did not
achieve remission had severe (at least one major BVAS/WG item) disease, and 5/17 patients (29%) received the higher glucocorticoid dosing regimen. 7/17 (41.2%) non-responders had previously received rituximab, median cumulative dose of 4125mg (1000-8930), which was comparable to responders (60/171 (35.1%); cumulative dose 3910mg (1500-16000)). At month 4, 3 patients had ongoing ENT disease activity; 3 had pulmonary manifestations; 2 had active renal disease, and 4 had other features of active disease (fatigue (2), pachymeningitis (1), headache (1)). None of the following baseline variables were predictive of disease response: age, ANCA type at enrolment, glucocorticoid induction regimen, presence of ear, nose, and throat or renal involvement (Supplementary Table 1), although it is notable non-severe disease was associated with an odds ratio of 2.93 CI(0.915,13.1) for subsequent response. Of the 17 patients who did not progress in the trial, only 6/188 (3.2%) had a failure to achieve disease control at month four, four died in the induction phase, two were withdrawn by their investigator (diagnosis of a new malignancy, occurrence of SAE), three withdrew consent, one required additional therapy not permitted in the protocol, and one failed screening and did not receive induction therapy.

Biochemical parameters:

Median B cell count fell from 0.12 x 10^9/l (12%) (range 0-3.49 (0-46%)) at baseline to 0 x 10^9/l (0%) (range 0-1 (0-3%)) at month 4. There was no difference in median B cell counts between responders and non-responders. There were modest reductions in c-reactive protein levels (median 2.65 mg/l (0-165) at baseline; 1.2 mg/l (0-183) at month 4) and erythrocyte sedimentation rate (21.5 mm/hour (1-149) to 12.5 mm/hour (2-100)) following treatment with glucocorticoids and rituximab. Serum creatinine remained stable (92.5 µmol/l (37.1-472) at baseline and 97.3 µmol/l (42-542) at month 4). 130/188 (69.1%) patients tested positive for ANCA at baseline, and 81/188 patients (43.1%) at month 4. There was a greater proportion of PR3-ANCA positive patients who became ANCA negative (53.2% to 33.1%) compared to MPO-ANCA patients (14.9% to 12.4%) (Figure 3). The two individuals who switched from being ANCA negative at baseline, to PR3 ANCA positive at month 4 entered remission.

Safety:

41 serious adverse events (SAEs) occurred in 27 patients, including 13 severe infections (9 chest, 3 urinary, and 1 gastrointestinal infection) in 7 patients. 5/13 infections occurred within 4 weeks of the first induction dose of rituximab. In addition, there were 86 non-severe infections in 59 patients (Supplementary Table 2). 51 patients had an IgG level less than 5 g/l at some point during the induction phase (Table 2). Four patients (2.1%) died in the induction phase; causes of death included: pneumonia [2], cerebrovascular accident [1], and active vasculitis [1].
DISCUSSION:

These data from the induction phase of the RITAZAREM trial, the largest reported prospective cohort of patients with relapsing AAV, demonstrate that rituximab, in conjunction with glucocorticoids, is effective at re-inducing remission in patients with AAV who have relapsed, regardless of previous therapy. A high proportion of patients (171/188, 90%) achieved remission by four months, and it is notable that 71% of patients received the lower-dose glucocorticoid regimen. Although there are retrospective series, the only previous prospective data on induction of remission for this subgroup of patients with ANCA-associated vasculitis was from the RAVE trial that observed a higher rate of remission in 50 relapsing patients treated with rituximab when compared to 50 relapsing patients treated with cyclophosphamide.(7, 11-15). Thus, these data confirm and extend the data on the efficacy of rituximab for relapsing GPA/MPA and supports a recommendation of rituximab for this indication.

The higher remission rate found in RITAZAREM versus RAVE may be due in part to the different definitions of remission. In RITAZAREM, remission was defined as a BVAS/WG ≤ 1 with a prednisolone dose ≤10 mg/day. The RAVE trial observed a lower remission rate of 64% at 6 months, but required a BVAS/WG of zero and complete glucocorticoid withdrawal.(7) The stricter definition of remission in RAVE, together with differences in trial design, and the enrollment in RAVE of a more severely affected patient population (median BVAS/WG 8.5 (5-13) for patients treated with rituximab), makes direct comparison between RITAZAREM and RAVE difficult. In the current study, only 6 of the 17 patients who did not achieve remission, (3.2% of the whole study population) clearly represented failure of the therapy. The remainder were withdrawn from the study protocol either due to investigator or participant decision (7 patients, 3.7%), or died (4 patients, 2.1%) within the induction phase. In this cohort, no baseline variables studied were predictive of failure of treatment response, although the small numbers of non-responders make it difficult for such an analysis to be definitive.

Induction regimens in AAV have been associated with high rates of serious adverse events and these are more frequent and problematic than failures to control disease activity, thus improvements in the safety of induction regimens are required. In RITAZAREM SAEs occurred in 14.3% of patients which is a lower rate than seen in the RITUXVAS trial in which 42% of patients treated with rituximab experienced at least one SAE, and the RAVE trial in which 22% of patients experienced at least one Grade 3 adverse event(6, 7).

In the treatment of AAV concomitant use of glucocorticoids is a major contributor to SAEs, especially infective risks, and two glucocorticoid regimens were permitted in this study to suit physician preference. The choice of glucocorticoid regimen was not randomized, and thus may have been subject to bias, so the relative efficacy of these two regimens cannot be completely analyzed. Nonetheless, these two regimens appeared similarly effective with the lower-dose approach providing approximately two-thirds of the total oral glucocorticoid exposure, and thus reduced dose glucocorticoids can be recommended as a treatment option for this indication.
The key strength of the study lies in the number of patients recruited, making this the largest cohort of patients with relapsing AAV to be studied in a clinical trial, facilitating the collection of high quality efficacy and safety data on a complex patient population. This is a typical population of patients relapsing with AAV, enriched for patients with PR3 ANCA positivity, with median prior disease duration of 5 years, prior exposure to cyclophosphamide and/or rituximab in the majority, and a degree of established chronic damage, meaning that results are broadly applicable. A potential weakness of this study was the option for investigators to choose, rather than randomly assigning the glucocorticoid dosing regimen in a blinded manner. Prescribing practices for use of glucocorticoids in AAV vary, necessitating a pragmatic approach to trial design. However, investigators were required to select the dosing regimen at enrolment, and tapering schedules were standardised.

Achieving a negative serum ANCA test following induction therapy is associated with a lower subsequent risk of relapse in AAV(16,17). In the current study, despite 90% of patients achieving remission at month 4, 46% remained positive for serum ANCA at month 4, supporting data from the RAVE trial, in which 53% of patients treated with rituximab remained positive for ANCA at 6 months(7) Follow-up in the randomized phase of the RITAZAREM trial will provide further insight into the significance of changes in ANCA levels.

These data from the first phase of RITAZAREM demonstrate that rituximab, in conjunction with even relatively low doses of glucocorticoids, is highly effective at re-inducing remission in patients with AAV who have relapsed, with a safety profile similar to or better than previous studies.
<table>
<thead>
<tr>
<th></th>
<th>Total (N=188)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years: median (range)</td>
<td>59 (19-89)</td>
</tr>
<tr>
<td>Male, number (%)</td>
<td>95 (51%)</td>
</tr>
<tr>
<td>Race, number (%)</td>
<td></td>
</tr>
<tr>
<td>- White</td>
<td>168 (89.4%)</td>
</tr>
<tr>
<td>- Asian</td>
<td>13 (6.9%)</td>
</tr>
<tr>
<td>- Hispanic</td>
<td>3 (1.6%)</td>
</tr>
<tr>
<td>- Black</td>
<td>1 (0.5%)</td>
</tr>
<tr>
<td>- Other</td>
<td>3 (1.6%)</td>
</tr>
<tr>
<td>Disease duration, years: median (range)</td>
<td>5.0 (0.4-34.5)</td>
</tr>
<tr>
<td>Prior treatment with cyclophosphamide</td>
<td></td>
</tr>
<tr>
<td>Number of patients (%)</td>
<td>149 (79.3%)</td>
</tr>
<tr>
<td>Cumulative dose, grams (g): median (range)</td>
<td>9 (0.15-301)</td>
</tr>
<tr>
<td>Prior rituximab therapy</td>
<td></td>
</tr>
<tr>
<td>Number of patients (%)</td>
<td>67 (35.6%)</td>
</tr>
<tr>
<td>Cumulative dose, grams (g): median (range)</td>
<td>3910 (1000-16000)</td>
</tr>
<tr>
<td>Glucocorticoid induction regimen</td>
<td></td>
</tr>
<tr>
<td>1 mg/kg/day starting dose (1A)</td>
<td>54 (28.7)</td>
</tr>
<tr>
<td>0.5 mg/kg/day starting dose (1B)</td>
<td>134 (71.3)</td>
</tr>
<tr>
<td>ANCA type</td>
<td></td>
</tr>
<tr>
<td>Anti-proteinase 3</td>
<td>137 (72.9%)</td>
</tr>
<tr>
<td>Anti-myeloperoxidase</td>
<td>51 (27.1%)</td>
</tr>
<tr>
<td>Relapse type upon entry into trial</td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>119 (63.3%)</td>
</tr>
<tr>
<td>Non-severe</td>
<td>69 (36.7%)</td>
</tr>
<tr>
<td>BVAS/WG: median (range)</td>
<td>5 (3-14)</td>
</tr>
</tbody>
</table>
Table 2: Adverse events according to glucocorticoid induction regimen

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>1A</th>
<th>1B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Number (%) of participants with an SAE</td>
<td>27 (14.3)</td>
<td>10 (18.5)</td>
<td>17 (12.7)</td>
</tr>
<tr>
<td>Total Number (%) of participants with a serious infection</td>
<td>7 (3.7)</td>
<td>0</td>
<td>7 (5.2)</td>
</tr>
<tr>
<td>Total Number (%) of participants with a non-serious infection</td>
<td>59 (31.4)</td>
<td>12 (22.2)</td>
<td>47 (35.1)</td>
</tr>
<tr>
<td>Number (%) of participants with IgG &lt; 5 g/L</td>
<td>51 (27.1)</td>
<td>27 (50.0)</td>
<td>24 (25.4)</td>
</tr>
</tbody>
</table>

1A: higher dose glucocorticoid induction regimen, starting at 1 mg/kg/day (maximum starting dose 60 mg/day); 1B: lower dose glucocorticoid induction regimen, starting at 0.5 mg/kg/day (maximum starting dose 30 mg/day).

Figure Legends:

Figure 1: Consort Diagram

Figure 2: Disease response according to baseline BVAS/WG score

Figures represent the number of individuals according to disease status. In addition to those displayed on the graph: at month 1.5, two individuals had severe disease, and 4 were withdrawn/missing. At month 3, one individual had severe disease and one limited disease. At month 4, one individual had severe disease, 3 limited disease and 3 persistent disease. Withdrawn/missing includes all participants who did not attend a study visit either due to death, withdrawal from trial or a missed visit.

Figure 3: Change in ANCA status between Month 0 and Month 4

Only complete cases reported (n=158). Figures represent the number of individuals according to ANCA status. In addition to those displayed on the graph, two individuals were positive for MPO and PR3 ANCA at month 0.
Figure 1: Consort diagram

- **Screening**: Patients enrolled (N = 188)
  - Withdrawn (N = 1)
    - Death (N = 0)
    - Withdrawal of consent (N = 0)
    - Investigator decision (N = 1)
    - Other (N = 0)

- **Month 0**: Induction therapy with rituximab (N = 187)
  - Withdrawn from study (N = 3)
    - Death (N = 2)
    - Withdrawal of consent (N = 1)
    - Investigator decision (N = 0)
    - Other (N = 0)

- **Month 1.5**: Active patients (N = 184)
  - Withdrawn from study (N = 4)
    - Death (N = 1)
    - Withdrawal of consent (N = 2)
    - Investigator decision (N = 1)
    - Other (N = 0)

- **Month 3**: Active patients (N = 180)
  - Withdrawn from study (N = 1)
    - Death (N = 1)
    - Withdrawal of consent (N = 0)
    - Investigator decision (N = 0)
    - Other (N = 0)

- **Month 4**: Completed induction phase (N = 179)
  - Not eligible for randomisation (N = 9*)
    - Death (N = 0)
    - Not in remission at month 4 (N = 6)
    - Participant decision (N = 0)
    - Investigator decision (N = 1)
    - Other (N = 2)

- **Randomisation**: Patients randomised to rituximab or azathioprine maintenance therapy (N = 170)
**Figure 2: Disease response according to baseline BVAS/WG score**

Figures represent the number of individuals according to disease status. In addition to those displayed on the graph: at month 1.5, two individuals had severe disease, and 4 were withdrawn/missing. At month 3, one individual had severe disease and one limited disease. At month 4, one individual had severe disease, 3 limited disease and 3 persistent disease. Withdrawn/missing includes all participants who did not attend a study visit either due to death, withdrawal from trial or a missed visit.
Figure 3: Change in ANCA status between Month 0 and Month 4

Only complete cases reported (n=158). Figures represent the number of individuals according to ANCA status. In addition to those displayed on the graph, two individuals were positive for MPO and PR3 ANCA at month 0.
**Supplementary Table 1: Effect of baseline variables on disease response at 4 months (unadjusted regression analysis)**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Estimate</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANCA status at enrolment (anti-MPO vs. anti-PR3)</td>
<td>1.23</td>
<td>0.412-4.54</td>
<td>0.727</td>
</tr>
<tr>
<td>Type of relapse (non-severe vs. severe)</td>
<td>2.93</td>
<td>0.915-13.1</td>
<td>0.101</td>
</tr>
<tr>
<td>Glucocorticoid induction regimen (1B vs. 1A)</td>
<td>1.04</td>
<td>0.316-2.96</td>
<td>0.948</td>
</tr>
<tr>
<td>BVAS/WG score</td>
<td>0.878</td>
<td>0.712-1.1</td>
<td>0.236</td>
</tr>
<tr>
<td>Ear, nose and throat involvement (No vs. Yes)</td>
<td>0.924</td>
<td>0.327-2.83</td>
<td>0.884</td>
</tr>
<tr>
<td>Renal involvement (No vs. Yes)</td>
<td>1.5</td>
<td>0.534-4.36</td>
<td>0.444</td>
</tr>
<tr>
<td>Age (years)</td>
<td>1.02</td>
<td>0.983-1.05</td>
<td>0.339</td>
</tr>
</tbody>
</table>

1A: higher dose glucocorticoid induction regimen, starting at 1 mg/kg/day (maximum starting dose 60 mg/day); 1B: lower dose glucocorticoid induction regimen, starting at 0.5 mg/kg/day (maximum starting dose 30 mg/day).
# Supplementary Table 2: Line listing of severe adverse events

<table>
<thead>
<tr>
<th>System Order Class (SOC)</th>
<th>Preferred Term (PT)</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac disorders</td>
<td>Acute coronary syndrome</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Cardiac arrest</td>
<td>1</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Abdominal pain</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Duodenal ulcer</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal haemorrhage</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Intestinal perforation</td>
<td>1</td>
</tr>
<tr>
<td>Immune system disorders</td>
<td>Vasculitis</td>
<td>3</td>
</tr>
<tr>
<td>Infections and infestations</td>
<td>Gastroenteritis Escherichia coli</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Pneumonia/respiratory tract infection</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Urinary tract infection</td>
<td>3</td>
</tr>
<tr>
<td>Injury, poisoning, procedural</td>
<td>Wound dehiscence</td>
<td>1</td>
</tr>
<tr>
<td>Complications / investigations</td>
<td>Medical observation</td>
<td>1</td>
</tr>
<tr>
<td>Malignancy</td>
<td>B-cell lymphoma</td>
<td>1</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Cerebrovascular accident</td>
<td>1</td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
<td>Enterovesical fistula</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Renal impairment</td>
<td>1</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Laryngeal stenosis</td>
<td>3</td>
</tr>
<tr>
<td>Surgical and medical procedures</td>
<td>Small intestinal resection</td>
<td>1</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td>Aortic dissection</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Deep vein thrombosis</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Pulmonary embolism</td>
<td>3</td>
</tr>
</tbody>
</table>
REFERENCES:


